February 22, 2019. NCHR supports the FDA’s issued guidance regarding sunscreen sold over-the-counter that contains ingredients not thoroughly studied.
Read More »On Medical Treatments & Products
Statement on Behalf of Members of the Patient, Consumer, and Public Health Coalition at the FDA Advisory Committee on Vaginal Mesh
February 12, 2019. NCHR testified at the FDA regarding vaginal mesh and its harm on patients. Mesh went through a lax approval process and was not proven to be safe before use.
Read More »NCHR Testimony at FDA on Esketamine for Treatment Resistant Depression
February 12, 2019. The data from the clinical trials for esketamine nasal spray are encouraging, but there are still important questions concerning its safety and efficacy.
Read More »Cancer Prevention and Treatment Funds’ Comments On USPSTF Draft Recommendation Statement for Breast Cancer: Medication Use to Reduce Risk
February 11, 2019. CPTF comments on the USPSTF breast cancer medications such as tamoxifen and raloxifene that are used to reduce risk in patients.
Read More »The USPSTF Draft Recommendations on Medication Use to Prevent Breast Cancer: Comments by Women’s Health Experts
February 11, 2019. NCHR writes on behalf of five nonprofit health organizations that have examined issues pertaining to primary prevention of breast cancer for decades and urge the USPSTF to consider revising their current recommendations on breast cancer risk reducing drugs.
Read More »